CD8A and neoplasm: To confirm the causal involvement of effector CD8+ T and NK cells in the anti-tumor effect triggered by the triple combination therapy, in vivo depletion of CD8+, NK1.1+ or both cell populations was performed in LLC-tumor-bearing mice (figure 4A).